Who wins and loses when brands struggle with cost barriers and limited market access?
Market barriers affect just over 20 percent of rheumatoid arthritis (RA) prescriptions in the US. High costs and limited formulary access are preventing rheumatologists we surveyed from prescribing some brands. Are they costing your brand market share, or are you winning share from more expensive competitors? Which other barriers are keeping doctors from prescribing your brand?
Get the answers in Market Access Impact: Rheumatoid Arthritis (US).
Based on a survey of 100 rheumatologists, the report covers 11 major therapies from AbbVie, Amgen, Bristol-Myers Squibb, Janssen Biotech, Regeneron, Sanofi, Pfizer, Roche, and UCB. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.
Not your market? Click here to see the EU5 Edition.
Market Access Impact: Rheumatoid Arthritis (US) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access:
How barriers affect your brand:
We surveyed 100 US-based rheumatologists, chosen from the largest community of validated physicians in the world.
All respondents have:
We conducted the survey between November 3-9, 2017.
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
Learn more at www.firstwordgroup.com.
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved